Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Plant Health Care Plc | PHC | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 8.925 | 00:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 8.925 |
| Industry Sector |
|---|
| CHEMICALS |
| Top Posts |
|---|
Posted at 03/6/2024 06:35 by robsy2 Interesting posts , I dithered and delayed and finally bought a small holding at 5p, I'd been thinking of pulling the trigger at 3pish but didn't ....The new research out this morning is quite bullish and suggests that if the market doesn't re rate this then a bidder could come along. It has been a long road to success but they seem to be within touching distance of being profitable . This feels like a significant moment. They say We highlight that approaching profitability is a major milestone as that not only significantly lowers the company’s cost of capital, but it also makes the company a much more attractive acquisition target. With such a profitable and proven biological agribiotech solution, we see Plant Health Care as a high-tech AIM-listed company that is at risk of being taken out before investors can enjoy the returns that are now visible after decades of development and investment. We see Plant Health Care as an undervalued acquisition target that is trading at a discount to the $30m it has invested in PREtec over a decade. Harpin is now delivering a CAGR of around 20% and the PREtec platform is delivering a pipeline of products with excellent on-ground performance, multi-million dollar high-margin revenues – and this is even before its most exciting product, the biological nematicide PHC949, is launched in Brazil this year. With Plant Health Care forecast to trade profitably within a year from now, we see the company as undervalued and at risk of being acquired by a much larger agritech company. We note that the risk of acquisition increases significantly as a tech company nears or reaches profitability, as this derisks the decision making for the acquirer. For a perspective on valuation, Plant Health Care’s closest listed comparable, Biotalys, is pre-revenue with a €20m cost base and a €96m market cap. |
Posted at 22/4/2024 11:51 by pretax2 I agree with comments above. Some excellent sounding news with limited detail. Time for an investor meet company session and a trading update. |
Posted at 22/4/2024 08:30 by kaos3 i have a problem. and most investors probably too.i can not understand the impact - how much, when, what growth rate, what capital needed, what margin ... of the news like today so i just do nothing give us some small salient small print next time with the RNS imho |
Posted at 20/4/2024 15:50 by cerrito Good question slicethepie as to when they get taken out.Industry players appear to have a different view of PHC prospects than Cavendish with their 42p target price and I am a bit uncomfortable that in all these months that the share price has been in the 3's that no-one has come on big to replace Mr Griffiths. My question mark and indeed concern is how Ispraie see this. I have no insight into their level of patience/requirement for liquidity nor indeed of their investors. The mind boggles as to what would happen to he share price if they followed-or tried to follow-Mr Griffiths to the exit door. |
Posted at 07/4/2024 14:31 by cerrito Note there is a US non listed company called Indigo Ag which I heard about reading comments on MNTN whose valuation declined in 2023 from £15.8m to £££800k.The problems in this company were largely self inflicted as they expanded into too many product areas. Last August they launched in the US a bionematicide to fight soybean cyst nematode. Comments about this company’s travails is that they are in an industry of slow adapters and also a comment from an investor that quote “It is investors acknowledging that many of these agtech companies are not ‘tech’ companies, they are simply ‘tech enabled,’ which has a very different multiple of dynamics such as margins and marginal cost structure.unquote Perhaps provides some insight into how PHC-rightly or wrongly-is seen in the US investment community. |
Posted at 22/11/2023 23:37 by cerrito I woke up Wednesday very long and very wrong on PHC and went to bed even longer and wronger. The key that made me comfortable buying more is that they have no immediate need for funds-their equity raise in June was in retrospect a v good move.I note Cenkos/Cavendish remain comfortable having a positive ebitda next year(good as no interest or tax to pay) , as a result of expense reduction, though I have never had the feeling they have had much fat to cut. We have no info on the profitability of the different geographies. Given their business mix, Mexico profitability per sales is I assume the worst and I go on the basis that NA is more profitable than La as LA more of a start up.Remember NA sales in 2022 were usd 4.8m put of usd11.8m. Cavendish in their note referred to the FMC investor day on November 16 when FMC commented on destocking trends. Specifi Note that FMC talking about the effects of destocking continuing into H1 24. There is however the question that on September 25 in the interims PHC wrote quote With lower inventories and strong customer on-ground sales, we are expecting a strong second half of 2023 with material revenue growth anticipated.unquote. Given today's heavy trading activities with 33m shares traded we await with interest any TR1's.I have to say that in some way with the current msrcap(even if sterling is currently stronger against the dollar than it has been for much of the last year), I would be worried if we did not get a takeover bid as it would suggest that PHC is not undervalued. |
Posted at 26/9/2023 09:06 by callumross There is an Investor Meets presentation at 4pm tomorrow which you can sign up to and no doubt you can obtain clarification on what criteria the $30m is based on. |
Posted at 22/6/2023 15:55 by cerrito Given that CR was very clear in the AGM where he would like to invest resources - as commented in my note-the fund raise no real surprise and may explain why in the last fortnight the share price has been muted despite the London Road show of the 2 Jeff's.Will in the coming month the share price dip below the 9p issue price as it so often does so that we disenfranchised retail investors can get it at 9p?? Possible but unlikely. Note that Osarie and Scobie Ward coming in. For all the talk of AIM being useless at raising capital, this is the second of my holdings that have done a fund raise in the last 24 hours-the other being Volex. I should have a winge that not invited to participate but note small amount of the issue and not a big discount so my heart not really into it. |
Posted at 14/6/2023 14:27 by cerrito I am glad I made the AGM yesterday and we had a very good hour mainly with CR. Two other investors there including Bots from LSE.The formal session took less than 5 minutes so we were able to cover alot of ground. The 2 Jeff's were in another meeting and came in at the end. Good division of labour as more important that they speak to prospective institutional investors. A propos the RNS this morning we were told that there would be 279 sales in the US this year but they would not move the dial. Remember they are being sold to the speciality market which means peak sales in the Spring and Autumn. The issue is that as discussed on IMC once Federal authorization has been obtained you need to get state authorization . This is a six week proceedure in all states except California where it is a question of years... Relevant as California is about 1/3rd of the US market. Harpin essentially the same for all products around the world. My notes which may be wrong tell me they have 20 people in Mexico and 12 in Brazil. Asked about the companies in the peptide space he admired, CR cited a US company Vestaron and Biotalys NV,a quoted Belgium company whose R&D spend is E18 m pa compared to the US3m that CR confirmed PHC expect to spend pa for the next couple of years and had operating income of E2m and a 2022 cash burn of E20m. As I understood it from CR, both companies have issues at getting the manufacturing issues sorted to lower production costs. What is interesting is that Biotalys had as per the Cenkos note a Marcap of £164m, ie 5x that of PHC. I did not get a sense at the meeting of the huge apparent discrepancy in Marcap between the two companies . Quite a bit of the meeting focused on the share price and also their desire but not need to raise cash for working capital requirements and to finance expansion in India and elsewhere. In the near term they are concentrating their efforts on 279 and 949. I do not see much chance of them getting debt finance. They have no hard fixed assets to pledge. CR was not keen on convertibles. CR confirmed that he was dead set against being taken over on the cheap. He confirmed what was implicit in the Result of the Consultation that there was no appetite among his shareholder base for them to do acquisitions which I am sympathetic to. He acknowledged there was market scepticism as there have been false starts including under his leadership.. I am not too aware of this as I bought my first shares in 2019. PS No real surprise that apart from the accounts all resolutions passed a la North Korea. Given the shareholder base would have expected a slightly higher voter turnout than 50pc, which is still respectable for an AIM company. Pps I did not ask specifically what future news flow there is. Obviously we get the interims in the next few months and last year we had a mid July IMC. Apart from that I cannot think of anything specific until we get full sign off from the various Brazilian authorities on 949. Ppps Silly me did not ask how US OTC market activity is nor rough percentage of shares held by UK retail. |
Posted at 26/4/2023 11:33 by pretax2 If you don’t mind me giving my own 2.5p worth.Both CR and JT have indicated that the share price should be higher. I asked CR why it was stagnating and he suggested that the company seemed to be viewed as a “show me” company. In other words show me that it works, show me that it sells, show me that you’re profitable. Up until last year I might have thought the same but things have fundamentally changed. PHC now has a suite of products; the products work brilliantly; revenue is growing towards profitability. But the big thing for me is climate change, energy change (biofuels), and a biblical food crisis. PHC have an answer for this - so the timing is right too. I guess all great companies start small and investors end up regretting they didn’t buy the shares way back “then” when the share price was peanuts. Well for PHC, this is the ‘peanuts’ 1.Profitability (especially if earlier than expected). 2. Takeover talk. PHC has destribution deals with a number of monster companies. There are also some interesting connections with Syngenta. 3/ Premise: The need for consolidation in the sector is well known and it’s starting to happen. Second, PHC is an American company keen to engage American investors. If you’ll forgive my fight of fancy, how about a reverse takeover of an American ag-tech company? If that happened hold onto your eyebrows, PHC shares would supernova. 4/ No reason at all. Many companies breakout from their doldrums for no apparent reason. There’s just a move to a more realistic value that gets bought into by traders. 5/ Press article. To me PHC has a really exciting story. The right article in the right journal at the right time and bingo. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
